Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brazikumab · 1 trial · 1 indication
Cmax of brazikumab in healthy Chinese and White participants will be evaluated.
AUCinf of brazikumab in healthy Chinese and White participants will be evaluated.
AUClast of brazikumab in healthy Chinese and White participants will be evaluated.
AUC0-28d of brazikumab in healthy Chinese and White participants will be evaluated.
| Arm | Type | Description |
|---|---|---|
| Group 1 [Healthy Chinese Participants] | EXPERIMENTAL | Participants will receive a single intravenous (IV) infusion of brazikumab dose 1 on Day 1. |
| Group 2 [Healthy Chinese Participants] | EXPERIMENTAL | Participants will receive a single IV infusion of brazikumab dose 2 on Day 1. |
| Group 3 [Healthy Chinese Participants] | EXPERIMENTAL | Participants will receive a single subcutaneous (SC) injection of brazikumab dose 3 on Day 1. |
| Group 4 [Healthy Chinese Participants] | EXPERIMENTAL | Participants will receive a single SC injection of brazikumab dose 4 on Day 1. |
| Group 5 [healthy White participants] | EXPERIMENTAL | Participants will receive a single IV infusion of brazikumab dose 2 on Day 1. |
| Group 6 [healthy White participants] | EXPERIMENTAL | Participants will receive a single SC injection of brazikumab dose 4 on Day 1. |
| Name | Type | Description |
|---|---|---|
| Brazikumab | DRUG | Participants will receive IV or SC injection of brazikumab as per the group they are assigned. |
Inclusion Criteria: * Participant is capable of giving signed and dated informed consent * Healthy Chinese and White male and female participants aged 18 to 55 years (inclusive), at the time of signing the informed consent * For White participants only: * Participant must be of European descent ...
Brazikumab is an investigational small molecule being studied in healthy participants. It is not approved for any disease and is currently in clinical development to evaluate its pharmacokinetics, safety, and tolerability. The drug is being tested in a Phase 1 trial involving healthy Chinese and White participants.
Brazikumab is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy participants.
Brazikumab is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial is designed to study the drug's movement within the body, safety, and tolerability in healthy participants.
Brazikumab is being studied in one completed Phase 1 clinical trial with the identifier NCT05033431. The trial, titled 'Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants,' enrolled 48 participants in the United States.
Brazikumab is a distinct investigational small molecule developed by AstraZeneca. No alternative names for this drug have been reported in the clinical trial information. It is being studied under its own name in a Phase 1 trial for healthy participants.